Skip to main content
. 2016 Apr 28;173(11):1820–1834. doi: 10.1111/bph.13481

Table 3.

Prospective pilot study for effect of liraglutide treatment on adipogenic, lipogenic and inflammatory marker gene expression in SAT from MO subjects treated with metformin

Liraglutide treatment
Before After Before After Before After
Age (in surgery, years) 44 44 48 48 51 51
Weight (kg) 137.5 136 146 143 158 156
BMI (kg·m−2) 54.5 54 50.1 49.8 56 55
Waist 139 138 132 130 149 147
HOMA‐IR 9.5 9.2 9.6 9.4 9.1 9
HbA1c 8.6 8.3 7.8 7.1 8.4 7.8
Glucose (mmol·L−1) 8.60 7.66 7.99 6.66 8.44 7.77
Triglycerides (mmol·L−1) 4.59 3.39 2.58 2.26 2.14 1.99
Cholesterol (mmol·L−1) 5.44 5.23 4.82 4.66 4.45 4.66
SBP 142 125 138 130 155 140
DBP 88 84 80 78 98 92
Adiponectin (2−ΔCt) 6.037 3.715 7.853 3.995 9.229 9.050
PPARγ (2−ΔCt) 0.081 0.071 0.089 0.079 0.097 0.086
FABP4 (2−ΔCt) 20.739 9.756 20.557 14.367 20.355 16.299
ADRP (2−ΔCt) 1.374 0.441 1.159 0.432 0.482 0.446
LPL (2−ΔCt) 1.419 0.987 1.606 1.298 1.792 1.225
Perilipin (2−ΔCt) 7.697 10.570 8.652 10.362 25.036 26.021
TNFα (2−ΔCt) 0.012 0.006 0.009 0.005 0.005 0.007

MO subjects (n = 3) with T2D being treated with metformin received a supplementary treatment of liraglutide for 1 month. Anthropometric parameters and gene expression of adipogenic, lipogenic and inflammatory markers in SAT were evaluated before and after 1 month of liraglutide treatment. RNA from patients was isolated from SAT, and then PPAR γ, FABP4, ADRP, adiponectin, LPL, perilipin and TNF‐α gene expression was measured by RT‐PCR. Signals were normalized to constitutively expressed cyclophilin using the formula 2−ΔCt. SBP, systolic blood pressure; DBP, diastolic blood pressure.